دورية أكاديمية
Survival analysis of dogs with advanced primary lung carcinoma treated by metronomic cyclophosphamide, piroxicam and thalidomide.
| العنوان: | Survival analysis of dogs with advanced primary lung carcinoma treated by metronomic cyclophosphamide, piroxicam and thalidomide. |
|---|---|
| المؤلفون: | Polton G; North Downs Specialist Referrals, Brewerstreet Dairy Business Park, Surrey, UK., Finotello R; Department of Small Animal Clinical Science, Institute of Veterinary Science, Faculty of Health and Life Science, University of Liverpool, Neston, UK., Sabattini S; Department of Veterinary Medical Sciences, University of Bologna, Bologna, Italy., Rossi F; Centro Oncologico Veterinario, Sasso Marconi, Italy., Laganga P; Centro Oncologico Veterinario, Sasso Marconi, Italy., Vasconi ME; Centro Veterinario Torinese, Turin, Italy., Barbanera A; Centro Oncologico Veterinario, Sasso Marconi, Italy., Stiborova K; Department of Small Animal Clinical Science, Institute of Veterinary Science, Faculty of Health and Life Science, University of Liverpool, Neston, UK., Rohrer Bley C; Division of Radiation Oncology, Vetsuisse-Faculty, University of Zurich, Zürich, Switzerland., Marconato L; Centro Oncologico Veterinario, Sasso Marconi, Italy. |
| المصدر: | Veterinary and comparative oncology [Vet Comp Oncol] 2018 Sep; Vol. 16 (3), pp. 399-408. Date of Electronic Publication: 2018 Mar 06. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Blackwell Country of Publication: England NLM ID: 101185242 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5829 (Electronic) Linking ISSN: 14765810 NLM ISO Abbreviation: Vet Comp Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Oxford, UK : Blackwell, [2003]- |
| مواضيع طبية MeSH: | Antineoplastic Combined Chemotherapy Protocols/*administration & dosage , Carcinoma/*veterinary , Cyclophosphamide/*administration & dosage , Dog Diseases/*drug therapy , Lung Neoplasms/*veterinary , Piroxicam/*administration & dosage , Thalidomide/*administration & dosage, Administration, Metronomic/veterinary ; Animals ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carcinoma/drug therapy ; Carcinoma/mortality ; Carcinoma/therapy ; Combined Modality Therapy/veterinary ; Cyclophosphamide/therapeutic use ; Dog Diseases/mortality ; Dog Diseases/therapy ; Dogs ; Female ; Lung Neoplasms/drug therapy ; Lung Neoplasms/mortality ; Lung Neoplasms/therapy ; Male ; Piroxicam/therapeutic use ; Survival Analysis ; Thalidomide/therapeutic use |
| مستخلص: | Unresectable or metastatic (advanced) primary pulmonary carcinoma (PPC) represents a therapeutic challenge where surgery may be contraindicated and the therapeutic role of maximum-tolerated dose (MTD) chemotherapy remains uncertain. This study was undertaken to explore the impact of metronomic chemotherapy (MC) in dogs with advanced PPC. Previously untreated dogs with advanced (T3 or N1 or M1) PPC, with complete staging work-up and follow-up data, receiving MC (comprising low-dose cyclophosphamide, piroxicam and thalidomide), surgery, MTD chemotherapy or no oncologic treatment were eligible for inclusion. For all patients, time to progression (TTP) and survival time (ST) were evaluated. Quality-of-life (QoL) was only evaluated in patients receiving MC. To assess QoL, owners of dogs receiving MC were asked to complete a questionnaire before and during treatment. Ninety-one dogs were included: 25 received MC, 36 were treated with surgery, 11 with MTD chemotherapy and 19 received no treatment. QoL was improved in dogs receiving MC. Median TTP was significantly longer in patients receiving MC (172 days) than patients undergoing surgery (87 days), receiving MTD chemotherapy (22 days), or no oncologic treatment (20 days). Median ST was similarly longer in patients receiving MC (139 days) than those undergoing surgery (92 days), MTD chemotherapy (61 days) and no oncologic treatment (60 days). In dogs with advanced PPC, MC achieved a measurable clinical benefit without significant risk or toxicity. This makes MC a potential alternative to other recognized management approaches. (© 2018 John Wiley & Sons Ltd.) |
| فهرسة مساهمة: | Keywords: advanced stage; canine; dog; lung carcinoma; metronomic chemotherapy; prognosis; thalidomide |
| المشرفين على المادة: | 13T4O6VMAM (Piroxicam) 4Z8R6ORS6L (Thalidomide) 8N3DW7272P (Cyclophosphamide) |
| تواريخ الأحداث: | Date Created: 20180307 Date Completed: 20181105 Latest Revision: 20181105 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1111/vco.12393 |
| PMID: | 29508493 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1476-5829 |
|---|---|
| DOI: | 10.1111/vco.12393 |